围手术期 MG 患者的管理及药物治疗的注意事项有哪些？

参考文献

[1] 谭群友,陶绍霖,刘宝东,等.重症肌无力外科治疗中国临床专家共识[J].中国胸心血管外科临床杂志,2022,29(05):529-541.

[2] 杨连凯.重症肌无力围手术期管理及肌无力危象的危险因素分析[D].郑州大学,2017.

[3] Blalock A, Mason MF, Morgan HJ, Riven SS. MYASTHENIA GRAVIS AND TUMORS OF THE THYMIC REGION: REPORT OF A CASE IN WHICH THE TUMOR WAS REMOVED. Ann Surg. 1939 Oct;110(4):544-61. 

[4] Wolfe GI, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. 

[5] 吴倩,司玉坤,李君莲,等.重症肌无力患者胸腺切除术后肌无力危象发生风险影响因素的Meta 分析[J].中国神经免疫学和神经病学杂志,2024,31(05):383-388.

[6] Takeuchi E, et al. The efficacy of eculizumab against post-thymectomy exacerbations in thymoma associated myasthenia gravis (MG). Rinsho Shinkeigaku. 2022 Apr 27;62(4):277-280. Japanese.